共 201 条
[61]
Wimberly H(2018)Lymphocyte-activation gene-3 expression and prognostic value in neoadjuvant-treated triple-negative breast cancer J Breast Cancer 30 530-undefined
[62]
Brown JR(2018)Evaluation of immune reaction and PD-L1 expression using multiplex immunohistochemistry in HER2-positive breast cancer: the association with response to anti-HER2 neoadjuvant therapy Clin Breast Cancer 18 4-undefined
[63]
Schalper K(2017)Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer J Clin Oncol 107 1730-undefined
[64]
Ghebeh H(2017)Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy Mod Pathol 9 23126-undefined
[65]
Mohammed S(2018)Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer BMC Cancer 1 448-undefined
[66]
Al-Omair A(2016)Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients Cancer Sci 379 2108-undefined
[67]
Schalper KA(2018)Differential prognostic impact of interleukin-34 mRNA expression and infiltrating immune cell composition in intrinsic breast cancer subtypes Oncotarget undefined undefined-undefined
[68]
Velcheti V(2015)Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial JAMA Oncol undefined undefined-undefined
[69]
Carvajal D(2018)Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer N Engl J Med undefined undefined-undefined
[70]
Bae SB(undefined)undefined undefined undefined undefined-undefined